Drug intelligence / Profile preview

MY006 (Mengyang Pharmaceutical)

Development stage: Preclinical
Lead developer: Mabylon
Modality: Small Molecules

Overview

MY006 is a small molecule, classified as a Class 1 Chemical Drug, being developed by Monyan Pharmaceutical for oncology supportive care. It is designed to address multiple complications associated with cancer and its treatment, including liver protection, improvement of heart function, increasing platelet counts, and managing cancer-related fatigue. As of 2024, the drug is in the IND-enabling stage, with clinical trial applications planned for that year.

Targets

Ara h 2

Beyond the preview

Go deeper on MY006 (Mengyang Pharmaceutical).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY006 (Mengyang Pharmaceutical).

Explore the full profile